PT3371316T - Vacinas contra o vírus da hepatite b - Google Patents

Vacinas contra o vírus da hepatite b

Info

Publication number
PT3371316T
PT3371316T PT167915735T PT16791573T PT3371316T PT 3371316 T PT3371316 T PT 3371316T PT 167915735 T PT167915735 T PT 167915735T PT 16791573 T PT16791573 T PT 16791573T PT 3371316 T PT3371316 T PT 3371316T
Authority
PT
Portugal
Prior art keywords
virus
vaccines against
against hepatitis
hepatitis
vaccines
Prior art date
Application number
PT167915735T
Other languages
English (en)
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of PT3371316T publication Critical patent/PT3371316T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10041Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT167915735T 2015-11-04 2016-11-03 Vacinas contra o vírus da hepatite b PT3371316T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04

Publications (1)

Publication Number Publication Date
PT3371316T true PT3371316T (pt) 2022-11-17

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167915735T PT3371316T (pt) 2015-11-04 2016-11-03 Vacinas contra o vírus da hepatite b

Country Status (20)

Country Link
US (2) US11214598B2 (pt)
EP (2) EP3371316B1 (pt)
JP (4) JP6914950B2 (pt)
KR (2) KR20250107977A (pt)
CN (2) CN108779472B (pt)
AU (3) AU2016348675B2 (pt)
CA (1) CA3003557A1 (pt)
DK (1) DK3371316T3 (pt)
ES (1) ES2934698T3 (pt)
FI (1) FI3371316T3 (pt)
HR (1) HRP20221474T1 (pt)
HU (1) HUE060648T2 (pt)
IL (2) IL259077B2 (pt)
LT (1) LT3371316T (pt)
MX (2) MX2018005569A (pt)
PL (1) PL3371316T3 (pt)
PT (1) PT3371316T (pt)
SG (1) SG11201803474UA (pt)
SI (1) SI3371316T1 (pt)
WO (1) WO2017076988A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
CN115197965A (zh) 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
FI3526323T3 (fi) 2016-10-14 2023-06-06 Prec Biosciences Inc Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
KR20220041080A (ko) * 2019-06-18 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 항-pd-1 또는 항-pc-l1 항체의 조합
US20220226467A1 (en) * 2019-06-18 2022-07-21 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
EP4458975A3 (en) * 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
WO2022226242A1 (en) * 2021-04-21 2022-10-27 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN121866044A (zh) 2023-09-15 2026-04-14 吉利德科学公司 沙粒病毒制剂、方法及其用途
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) * 1996-09-19 1998-04-07 Fujirebio Inc B型肝炎のe抗原
KR100715954B1 (ko) * 1998-12-04 2007-05-09 바이오겐 아이덱 엠에이 인코포레이티드 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 hbv 코어 항원 입자
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
EP1888622A1 (en) * 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2947292C (en) * 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
LT2604695T (lt) * 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
JP5745102B2 (ja) * 2011-02-12 2015-07-08 グローブイミューン,インコーポレイテッド 慢性b型肝炎感染症のための酵母系免疫療法組成物
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6219849B2 (ja) 2012-01-24 2017-10-25 サンフォード ヘルス 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
PL3198008T3 (pl) 2014-09-22 2020-03-31 Regents Of The University Of Minnesota Układ wykorzystujący odwrotną genetykę wirusa pichinde i sposoby zastosowania
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
RS60937B1 (sr) * 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN115197965A (zh) 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
US10849969B2 (en) 2015-10-23 2020-12-01 Institut Pasteur Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
CN117486979A (zh) 2016-05-18 2024-02-02 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
WO2018083220A2 (en) 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en) 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
EP3371316B1 (en) 2022-10-19
EP3371316A1 (en) 2018-09-12
JP2024010027A (ja) 2024-01-23
IL259077B1 (en) 2024-08-01
MX2023013140A (es) 2023-11-28
CA3003557A1 (en) 2017-05-11
DK3371316T3 (da) 2023-01-23
KR102832178B1 (ko) 2025-07-11
JP7777907B2 (ja) 2025-12-01
SG11201803474UA (en) 2018-05-30
JP2026036693A (ja) 2026-03-05
ES2934698T3 (es) 2023-02-24
US11214598B2 (en) 2022-01-04
JP2018536433A (ja) 2018-12-13
PL3371316T3 (pl) 2023-02-13
AU2016348675A1 (en) 2018-05-17
HUE060648T2 (hu) 2023-04-28
AU2016348675B2 (en) 2022-11-17
WO2017076988A1 (en) 2017-05-11
AU2023200108B2 (en) 2025-08-28
LT3371316T (lt) 2022-11-25
CN108779472B (zh) 2022-09-09
BR112018009032A8 (pt) 2019-02-26
AU2025271193A1 (en) 2026-01-15
JP6914950B2 (ja) 2021-08-11
JP2021182922A (ja) 2021-12-02
KR20180082485A (ko) 2018-07-18
SI3371316T1 (sl) 2023-02-28
IL314371A (en) 2024-09-01
HRP20221474T1 (hr) 2023-01-06
NZ741950A (en) 2023-10-27
HK1255847A1 (en) 2019-08-30
IL259077A (en) 2018-06-28
EP4177348A1 (en) 2023-05-10
NZ781654A (en) 2025-06-27
US20180319845A1 (en) 2018-11-08
FI3371316T3 (fi) 2023-01-13
CN108779472A (zh) 2018-11-09
US20220073568A1 (en) 2022-03-10
CN115948467B (zh) 2026-04-24
AU2023200108A1 (en) 2023-02-16
BR112018009032A2 (pt) 2018-11-06
IL259077B2 (en) 2024-12-01
CN115948467A (zh) 2023-04-11
KR20250107977A (ko) 2025-07-14
MX2018005569A (es) 2018-12-19

Similar Documents

Publication Publication Date Title
SG11201803474UA (en) Vaccines against hepatitis b virus
SMT202200361T1 (it) Vaccini contro virus respiratori
HUE061679T2 (hu) Zika vírus vakcina
SG10201913630YA (en) Zika virus vaccine
EP3713601A4 (en) VACCINES AGAINST EPSTEIN-BARR VIRUS
ZA201700165B (en) Influenza virus vaccines and uses thereof
GB201406608D0 (en) Virus
GB201613191D0 (en) Zika virus vaccine
IL263550A (en) Infectious bronchitis virus vaccine
IL247185B (en) Tilapia virus vaccines
GB201419572D0 (en) Virus
SG11201808268UA (en) Recombinant hansenula-based high dosage hepatitis b vaccine
GB201702193D0 (en) Hepatitis E virus vaccine
IL254648A0 (en) Vaccines based on hepatitis b core antigens
GB201605099D0 (en) HCV vaccines
SG11201507455WA (en) Hepatitis b virus vaccines
GB201615311D0 (en) Virus, Vaccine cures
HK1259941A1 (en) Respiratory virus vaccines
PT3393510T (pt) Vacina contra o vírus zika
GB201522013D0 (en) Virus
GB201716047D0 (en) Virus
GB201516936D0 (en) Virus
IL249705B (en) Influenza virus vaccines and their uses
IL249704A0 (en) Influenza virus vaccines and their uses
GB201600380D0 (en) Modified virus